CompletedPhase 2

Safety and Efficacy of Repeat Use of Picato® 0.05% in the Treatment of Anogenital Warts

Denmark40 participantsStarted 2015-02

Plain-language summary

An exploratory open label, single treatment trial of anogenital warts with Picato® repeated up to 2 times with two weeks intervals.

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✕. Known human immunodeficiency virus (HIV) infection
✕. An outbreak of herpes genitalis in the wart areas within 4 weeks prior to enrolment
✕. Has internal (rectal urethral, vaginal/cervical) warts that require or are undergoing treatment
✕. Has a dermatological disease (e.g. psoriasis) or skin condition in the wart areas

Number of incidence and severity of Local Skin Reactions (LSR)

Timeframe: Measured two weeks after every treatment and final measurement 2 weeks after last treatment

NCT IDNCT02377999

SponsorLEO Pharma

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2015-11